Kornimate/medical-research-clean huggingface dataset:
research on endoscopic precision biopsy.

Conditions: Colorectal Adenoma

Summary: colorectal adenoma is a common disease and frequently-occurring disease in gastroenterology. with the continuous progress of colonoscopy equipment and the gradual improvement of endoscopic accessories, especially the development of chromo-endoscopy and magnifying endoscopy. the observation of the surface structure and capillary morphology of colorectal adenomas can realize optical biopsy. currently, most clinical endoscopic diagnosis of colorectal diseases is biopsy under colonoscopy, and further treatment options are determined based on the pathological results of the biopsy. the problem is that the pathological diagnosis of some preoperative biopsy is not completely consistent with the pathological diagnosis of postoperative large specimens. previous studies have found that the pathological diagnosis accuracy rate of preoperative biopsy is only 66-75%, so there is a certain degree of subjectivity in relying solely on colonoscopy white light biopsy. based on the previous work, the research team has initially established an intelligent recognition model for colorectal adenoma classification (low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia), and formed a colorectal adenoma of a certain size with annotated endoscopic image data set. using the yolo-v4 algorithm, under the darknet framework, to train an artificial intelligence (ai) system which specifically for adenoma recognition and diagnosis, its accuracy rate has reached more than 90%. this study intends to increase the sample size based on the previous work, and further improve the accuracy of the classification and diagnosis of the ai system, so as to guide the endoscopist to perform targeted biopsy and improve the accuracy of preoperative biopsy.


Eligibility criteria:
inclusion criteria: * age between 30-75; * those who have no mental abnormality and can conduct questionnaire surveys; * bbps ≥ 6; * colorectal advanced adenoma, and admitted for complete resection with emr and esd; * provide the relevant information required by this study and sign the informed consent. exclusion criteria: * those who cannot provide the relevant information required by this research; * patients with inflammatory bowel disease; * those with a history of liver cirrhosis, uncontrolled hypertension, history of myocardial infarction, cardiac insufficiency, renal insufficiency, respiratory failure, diabetic ketosis and electrolyte imbalance and other serious diseases; * those who cannot stop antiplatelet drugs or anticoagulant drugs; * those who have not completed full colonoscopy; * pregnant women.

Keywords: ai system colonoscope guided biopsy
trial of savvy and hiv in ghana

Conditions: HIV Infections

Summary: heterosexual contact is now the primary route of transmission for hiv worldwide. this study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% c31g (savvy) vaginal gel for the prevention of male-to-female transmission of hiv among women at high risk.

heterosexual contact is now the primary route of transmission for hiv worldwide. this study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% c31g (savvy) vaginal gel for the prevention of male-to-female transmission of hiv among women at high risk.

Eligibility criteria:
inclusion criteria: * 18 to 35 year old women * hiv negative * more than one sexual partner in past 3 months * average of 3 coital acts per week * willing to use vaginal gel and condoms for 12 months exclusion criteria: * hiv positive * pregnant

Keywords: hiv transmission
the effectiveness of an online self-delivered death anxiety intervention

Conditions: Death Anxiety

Summary: the goal of this clinical trial is to examine the effectiveness of the online self-delivered death anxiety intervention developed by our team in the general population with a randomized controlled trial. the study will recruit 50 participants, with 25 randomized to the death anxiety intervention group and 25 randomized to the control group (waiting list). the online intervention on death anxiety consists of 4 phases that take about 2 hours in total. the primary outcome das (death anxiety scale) and dabbs (death anxiety beliefs and behaviors scale) will be administered on baseline, post-treatment, 1-month follow-up, and 3-month follow-up assessments.


Eligibility criteria:
inclusion criteria: * 18-65 years of age * normal literacy skills and ability to use a smartphone proficiently * higher death anxiety that is above the cutoff of our measurement * voluntarily participate in this intervention and be able to provide informed consent. exclusion criteria: * severe depressive state or risk of suicidal self-injury, i.e., the total score of patient health questionnaire 9-item ≥19 or the score of 9th item ≥2 * diagnosed within 6 months with schizophrenia, depression, bipolar disorder, and other psychiatric disorders * have received any intervention for death anxiety or cbt intervention on any topic within the past 6 months.

Keywords: death anxiety randomized controlled trial self-delivered
oral theraclec™ - total in cystic fibrosis subjects with exocrine pancreatic insufficiency

Conditions: Cystic Fibrosis; Pancreatic Insufficiency

Summary: the purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (cf) subjects with exocrine pancreatic insufficiency.


Eligibility criteria:
inclusion criteria: * pancreatic insufficiency (pi) documented by fecal elastase \<100 mcg/gram measured at screening * diagnosis of cf based upon the following criteria: * two clinical features consistent with cf and * either genotype with two identifiable mutations consistent with cf or * sweat chloride \> 60 meq/l by quantitative pilocarpine iontophoresis * forced expiratory volume over one second (fev1) ≥30% predicted * clinically stable with no evidence of acute upper or lower respiratory tract infection exclusion criteria: * pregnancy, breastfeeding or of childbearing potential and/or not willing to use accepted methods of birth control during enrollment in the study * history of fibrosing colonopathy * history of liver transplant or lung transplant * unable to discontinue enteral tube feedings during the study * subject weight \<40 kg * known hypersensitivity to food additives * participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to screening * unable to discontinue the use of pancreatic enzymes for a 72-hour period or any other condition that the investigator believes would interfere with the intent of this study or would make study participation not in the best interest of the subject

Keywords: pancreatic insufficiency cystic fibrosis enzymes
safety and tolerability of dabigatran etexilate solution in children 1 to < 12 years of age

Conditions: Venous Thromboembolism

Summary: to investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data

purpose:

Eligibility criteria:
inclusion criteria: 1. males or females 1 to less than 12 years of age 2. objective diagnosis of primary vte 3. completion of planned treatment course with lmwh or oac for primary vte 4. written informed consent by parent (legal guardian) and patient assent (if applicable) exclusion criteria: 1. weight less than 9 kg 2. conditions associated with increased risk of bleeding 3. patients who have any condition that would not allow safe participation in study note: further exclusion criteria apply
flourishing and virtue in cognitive-behavioral therapy for anxiety and depressive disorders

Conditions: Anxiety Disorders; Depressive Disorder

Summary: this two phase study is testing an online version of a transdiagnostic, cognitive behavioral therapy, against a modified version of that therapy emphasizing positive affect. the first phase of the trial will focus on content development for the modified therapy and the second phase will be a randomized control trial comparing the two.

research shows that positive emotions can buffer against the effects of stress as well as contribute to overall well-being and functioning. people with emotional disorders, such as anxiety and depression, often report lower levels of positive emotions. however, to date, most existing treatment approaches for emotional disorders focus on regulating negative emotions, without explicitly focusing on positive emotions. the unified protocol (up) is a transdiagnostic, cognitive-behavioral therapy that has been shown to be effective for treating emotional disorders. the up targets negative emotions and helps people respond to their emotions in ways that are more helpful for them and in line with their goals. in its current form, the up does not explicitly target positive emotions, but some research suggests that individuals treated with the up and other cognitive-behavioral treatments experience some improvement in positive affect. in the current study, the researchers will create a modified version of the up (called the up+) delivered entirely on an online platform that will include exercises specifically designed to enhance positive emotions. then, the researchers will evaluate the up+ in a small sample of participants to examine acceptability and feasibility and will then use this information to continue to refine the protocol. finally, the researchers will conduct a randomized controlled trial to assess the efficacy of the up+. participants diagnosed with emotional disorders will be randomized to either receive the up or the up+ delivered on an online platform and will be assessed on a range of outcomes, including positive and negative affect, psychological symptoms, and functional outcomes.

Eligibility criteria:
inclusion criteria: diagnosed with a dsm-5 anxiety, obsessive-compulsive, or depressive disorder exclusion criteria: acute risk factors (suicidal or homicidal ideation or clinical condition requiring immediate treatment); the individual is in treatment elsewhere for related issues; and/or the individual is considering changing their treatment and and/or psychotropic medication during the time period in which they would be enrolled in the study and/or the individual is unable or unwilling to commit to the study procedures.
efficacy and safety of atorvastatin and ezetimibe (10/10mg) fixed dose combination versus atorvastatin (20mg) monotherapy in bangladeshi population

Conditions: Hyperlipidemia (E.G., Hypercholesterolemia)

Summary: the goal of this clinical trial is to evaluate the efficacy and safety of a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy in the bangladeshi population. researchers will compare atorvastatin (10 mg) and ezetimibe (10 mg) to atorvastatin (20 mg) monotherapy to see if atorvastatin (10 mg) and ezetimibe (10 mg) fdc works to treat dyslipidemia. participants will: * take a fixed-dose combination of atorvastatin (10 mg) and ezetimibe (10 mg) compared to atorvastatin (20 mg) monotherapy for 3 months * follow-up visits at 6 weeks and 12 weeks for checkups and tests


Eligibility criteria:
inclusion criteria: * men and women aged \>18 years. * patients with a confirmed diagnosis of elevated ldl-c levels necessitating medical management. * patients in the low to moderate cardiovascular disease (cvd) risk category according to esc guidelines (2019) * low-risk: increased ldl-c level without any co-morbidities * moderate-risk: young patients (t1dm \<35 years; t2dm \<50 years) with dm duration \<10 years, without other risk factors. exclusion criteria: * history of hypersensitivity to any study drugs. * clinically significant hepatic impairment (alt, ast level \> 2xuln) and/or renal impairment (serum creatinine level ≥2xuln). * patients with hepatitis b virus (hbv) or hepatitis c virus (hcv) with cirrhosis, end-stage liver disease, cancer, psychiatric instability, hiv + status, intestinal malabsorption. * pregnant or lactating females. * the presence of a condition that, in the opinion of the investigator, would place the subject at increased risk from study participation.

Keywords: increased ldl-c level hyperlipidemia atorvastatin (10 mg) and ezetimibe (10 mg)
maternal antibody in milk after vaccination

Conditions: Pertussis; Vaccination; Pregnancy; Breastmilk

Summary: single-centre observational pilot study exploring pertussis specific antibody concentration in the breastmilk of women vaccinated against pertussis in pregnancy at different gestational ages. this study is made up of two stages: first stage to confirm recruitment methods and optimise the laboratory assay and a second stage to complete recruitment for the pilot study.

pertussis disease is a highly infectious respiratory illness caused by bordetella pertussis, which can cause significant morbidity and mortality. there has been an increase in cases in many high income countries with high vaccination coverage and in an attempt to control this, antenatal vaccination programmes have been introduced in several countries, including the uk. vaccination in pregnancy is a strategy which seeks to boost the maternal antibody levels, increase the placental transfer of antibody and consequently increase the antibody levels in the infant. human breast milk is a dynamic source of nutrition for the infant and is made up of many immunologically active components including antibody. the principal antibody in breastmilk is iga and it has been shown that the amount of disease specific antibody in breastmilk can be increased by vaccination in pregnancy for a number of pathogens including pertussis. secretory iga (siga) plays an important role in immune exclusion in which it blocks adhesion of a pathogen onto a mucosal surface. as the first step of pertussis pathogenesis is the adhesion of bacteria to the ciliated respiratory epithelium in the nasopharynx and trachea there is a clear biological rationale for the hypothesis that receiving breast milk containing more iga could enhance neonatal immunity and consequently the protective effects of vaccination in pregnancy. the best time in pregnancy for administering the pertussis vaccination is debated in the literature, with some advocating vaccination in the second trimester and others supporting later vaccination to coincide the time of serum antibody peak with optimum placental transfer. this issue has been considered exclusively from the perspective of serum immunoglobulin g (igg), but the impact of timing of vaccination in pregnancy on iga levels in milk may also be important. previous studies have shown that there is a peak in the pertussis specific iga in breast milk at day 10 following vaccination, which then declines, and consequently there may be a significant difference in the amount of iga available in the breastmilk for an infant born to a mother vaccinated at 20 weeks for example, compared to a mother vaccinated at 32 weeks. this may therefore have an impact on future guidelines on optimal time of vaccination in pregnancy.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * received pertussis vaccination between 16 and 32 gestational weeks * planning to breastfeed exclusion criteria: * received vaccination outside of the 16-32 week window * not planning to breastfeed * diagnosis of an immunodeficiency syndrome * multiple pregnancy
efficacy and safety of herombopag in patients with thrombocytopenia before hepatectomy

Conditions: Hepatopathy

Summary: this is a single center, randomized, controlled study, to evaluate the efficacy and safety of herombopag in patients with thrombocytopenia before hepatectomy.

the purpose of this study is to assess the ability of herombopag to elevate platelet counts thereby reducing the need for platelet transfusions in patients with thrombocytopenia before hepatectomy. the clinical benefit of herombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an hepatectomy. in addition, bleeding events will be monitored during this time. the number of transfusions, safety events will be monitored during this time and for up to 3 months after undergoing a hepatectomy to help further evaluate clinical benefit.

Eligibility criteria:
inclusion criteria: * 1. male and female subjects ≥18 years of age； * 2.patients prepared to receive hepatectomy； * 3.50×10\^9/l≤platelet count≤80×10\^9/l； * 4.child-pugh score a or grade b (≤7 )； * 5.life expectancy ≥3 months； * 6.normal bone marrow hematopoiesis and renal function; * 7.voluntary participation and written informed consent; exclusion criteria: * 1.central nervous system diseases caused by liver disease; * 2.platelet transfusion within 7 days prior to the first dose of study drug; * 3.history of any primary hematologic disorder; * 4.history of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system; * 5.pre-diagnosed immune thrombocytopenic purpura (itp); * 6.history of myelodysplastic syndrome (mds); * 7.those with bleeding tendency，have evidence of hereditary bleeding or blood coagulation disorder; * 8.females who are pregnant (positive β-hcg test ) or breastfeeding; * 9.subjects who have participated in another investigational trial within 30 days prior to visit 1; * 10.those with uncontrollable neurological and psychiatric diseases or mental disorders, poor compliance, unable to cooperate and describe treatment response; * 11.subjects with known intolerance or allergy to any of the ingredients in eltrombopag tablets;

Keywords: hepatopathy thrombocytopenia hetrombopag
dermatologists' educational demonstration for epiduo application

Conditions: Facial Acne; Local Adverse Effects

Summary: the purpose of this study is to evaluate the efficacy and tolerability of this combination gel compared with bpo monotherapy in korean patients, and test clinical practicability of dermatologists' educational demonstration for how to apply this gel in reducing uncomfortable irritations.


Eligibility criteria:
inclusion criteria: * mild to moderate acne were evaluated by leeds revised acne grade from 2 to 6 * age: 18-40 exclusion criteria: * pregnancy * mental illness * intake of oral isotretinoin within 6 months * application of the other oral or topical acne medications * chemical peeling or light based treatments within 6 weeks.
a phase iv clinical study to compared the efficacy and safety of switching metformin+sglt2-i+dpp4-i to metformin+sglt2-i+tzd in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: this is a randomized, open-label, active-controlled, parallel, multicenter, phase iv clinical study evaluating the efficacy and safety of switching metformin+sglt2-i+dpp4-i to metformin+sglt2-i+tzd in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * has voluntarily agreed to participate in this clinical trial. * adults over 19 years of age * diagnosed with type 2 diabetes exclusion criteria: * has severe renal and liver disorders * has type 1 diabetes * those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study * those who are deemed ineligible to participate in the study by the investigator

Keywords: type 2 diabetes
mobile micro-learning on nurses' self-confidence, motivation, and stress

Conditions: Cardiopulmonary Arrest; Nurse's Role

Summary: before and after effect of using mobile micro-learning on their self-confidence, motivation, and stress toward cardiopulmonary resuscitation.

this study aims to determine the effect of mobile micro-learning on critical care nurses' self-confidence, motivation, and stress after cardiopulmonary resuscitation. the current study will use three scales. self-confidence scale, cardiopulmonary motivation scale, and post-code stress scale. mobile micro-learning is used easily to access video-based learning tips for effective practice for cardiopulmonary resuscitation.

Eligibility criteria:
inclusion criteria: * critical care nurses who have worked in the intensive care unit for more than one year. exclusion criteria: * critical care nurses who have less than one year of experience.
a tasisulam and midazolam drug interaction study in cancer patients

Conditions: Advanced Cancer

Summary: the purpose of this study is to evaluate whether tasisulam acts as an inducer of cyp3a using midazolam as a sensitive and specific probe substrate of cyp3a. the study will also assess the safety and tolerability of tasisulam and midazolam given in combination and document any antitumor activity with tasisulam.


Eligibility criteria:
inclusion criteria: * have histologically or cytologically confirmed solid malignancy or lymphoma that is advanced and/or metastatic disease which has not responded to standard therapy or for which no standard therapy exists. * have a performance status of less than or equal to 2 on the eastern cooperative oncology group (ecog) scale * have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 30 days (45 days for mitomycin-c or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy. limited field radiotherapy is permitted (in consultation with the investigator) * have an estimated life expectancy, in the judgment of the investigator, of greater than or equal to 12 weeks exclusion criteria: * have received treatment within 30 days of the initial dose of study drug with an experimental agent for non-cancer indications that has not received regulatory approval for any indication * have symptomatic central nervous system (cns) malignancy or metastasis (screening not required). patients with active brain metastasis are excluded * have current acute or chronic leukemia * patients who have clinically significant chronic obstructive pulmonary disease (copd) or other respiratory diseases that may be at risk during periods of conscious sedation under midazolam * patients with a known history of obstructive sleep apnea, difficult intubation, or syndromes associated with airway abnormalities.

Keywords: metastatic tumors lymphoma